Dr. Kim Dao of the Knight Cancer Institute talks about the CALR (say it "cal R") factor in some ET patients. She gets a little technical at times, but the bottom line is that the discovery of CALR indicates that there are several "pathways" to ET, and researchers are trying to determine how those pathways affect ET progression, symptoms, and treatment differently.
The up side here is that the more pathways that are discovered, the more treatments can be targeted to individual ET patients for more successful treatment. The down side is that ET and other MPNs are complicated diseases, and that means that the one-size-fits-all treatments now available (oral chemo and JAK2 inhibitors) may not work for everyone and lots more research is needed.
Hang in there and be well!
Related: JAK-2 or CALR?
No comments:
Post a Comment
ET is a serious disease that requires specialist care. Discuss anything you read here with your doctor. No comments promoting "alternative" or "natural" cures (yes, this includes Rick Simpson's Oil) will be published.